Get access to our best features
Get access to our best features
Published

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

  • Biogen has announced that it will discontinue the sale and development of the Alzheimer's drug Aduhelm, refocusing efforts on their newly approved drug Leqembi.
  • The decision to drop Aduhelm is not due to safety or efficacy concerns, and the Swiss company Neurimmune will regain full rights to the medicine.
  • Biogen will redistribute resources from Aduhelm to other Alzheimer's treatments in their portfolio, such as BIIB080.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 61% of the sources are Center
60% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)